Cytokinetics, Incorporated Overview
Pro stress-test →Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of scientific innovations in muscle biology, advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. The company recently achieved FDA approval of MYQORZO™ (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy, with availability expected in the U.S. in January 2026.
Strategic Profile
Pro stress-test →Cytokinetics stands at a pivotal inflection point in 2026, driven by the imminent EU approval of MYQORZO for obstructive hypertrophic cardiomyopathy and a rapidly advancing pipeline of muscle biology-directed therapies. Topline results from the ACACIA-HCM trial for non-obstructive HCM are expected in H1 2026, with a dual-label strategy and direct-to-consumer commercial model potentially enhancing profit margins.
Competitive Landscape
Pro stress-test →Cytokinetics is advancing omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. The company competes in the cardiac therapeutics space with other myosin modifiers and heart failure drug developers. Direct-to-consumer commercialization for MYQORZO differentiates its approach from traditional pharma partnerships.
Industry Context
Cytokinetics, Incorporated operates in Specialty Cardiovascular Biopharmaceuticals.
Key facts
Founded: 1997 · Headquarters: South San Francisco, California · Employees: N/A · Revenue: N/A · Market cap: N/A